Snapshot from Aug 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / P&F acquires AVVie GmbH
Business acquisition

P&F acquires AVVie GmbH

Analysis based on 6 articles · First reported Aug 05, 2026 · Last updated Aug 05, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition is expected to strengthen P&F's structural heart portfolio and accelerate development of the AngelValve platform, potentially enhancing its competitive position in the transcatheter heart valve market. While financial terms were undisclosed, the deal may positively impact P&F's growth prospects and market sentiment, though the private nature of both companies limits direct market reaction.

Medical Devices Healthcare
Event Summary

On August 5, 2026, P&F Products & Features GmbH (P&F), a Vienna-based medical technology company, announced the acquisition of AVVie GmbH, a developer of the AngelValve Augmentation System, a transcatheter platform for treating mitral regurgitation. The acquisition combines AVVie's R&D and intellectual property with P&F's global development, regulatory, manufacturing, and commercialization capabilities. Financial terms were not disclosed. The deal aims to address the significant unmet need in mitral valve disease treatment, as only about 5% of the over 13 million patients in Europe and the United States with moderate to severe mitral regurgitation currently receive treatment. P&F's CEO Katharina Kiss and COO Siegfried Einhellig emphasized the strategic importance of the acquisition in advancing structural heart therapies and strengthening P&F's portfolio.

Key Actions
100 P&F Products & Features acquired AVVie GmbH
Entities Involved
priv
P&F Products & Features
Acquirer; strengthens structural heart portfolio with AngelValve, expanding its transcatheter heart valve offerings and reinforcing its commitment to structural heart innovation.
Importance 100.0 Sentiment 60.0
priv
AVVie GmbH
Acquired company; its AngelValve technology and R&D capabilities are integrated into P&F, providing resources for development and commercialization.
Importance 90.0 Sentiment 70.0
per
Werner Mohl
Founder of AVVie; his innovation is central to the acquisition, though his post-acquisition role is not specified.
Importance 40.0 Sentiment 50.0
cnt
United States
Major market for the AngelValve therapy, with a large patient population and potential for commercialization.
Importance 30.0 Sentiment 40.0
loc
Europe
Region with significant mitral regurgitation patient population; market for the AngelValve therapy.
Importance 30.0 Sentiment 40.0
per
Katharina Kiss
CEO of P&F; announced the acquisition and highlighted its strategic importance.
Importance 30.0 Sentiment 50.0
per
Siegfried Einhellig
COO and Head of R&D at P&F; commented on the combination of engineering talent and development capabilities.
Importance 20.0 Sentiment 50.0
cnt
Austria
Home country of P&F; the acquisition reinforces Austria's role in medical technology innovation.
Importance 20.0 Sentiment 40.0
Relationships
United States related ↔ Austria
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.